境外旅客或陸客的台灣醫療保險!!

台九家醫院 提供陸客醫療險服務【2011/11/26 聯合報】近年來台旅遊、洽公的大陸旅客越來越多，也吸引愈來愈多的保險公司投入，除了搶食大餅，也提供更多往返兩岸的旅客有醫療保障。衛生國際醫療管理工作小組昨與安聯全球救援集團的北京分公司簽署合作協議，日後來台的陸客或境外人士，只要購買相關旅遊保險，就能在全台九家協力醫院，得到完善醫療服務。 這九家醫院包括台安醫院、亞東醫院、署立雙和醫院、光田醫院、童綜合醫院、彰化基督教醫院、彰濱秀傳醫院、員榮醫院與聖馬爾定醫院等。不過，吳明彥也表示，不論是境外旅客或陸客，只要有投保旅遊平安保險，一旦在台發生緊急醫療事故，都有程度不同的保障，若發生事故，可詢問投保公司，接觸合作的全球救援機構，就能得到相關的醫療服務。

血糖測試族群 先紅海 在藍海!!

糖尿病人口漸增 血糖測試族群超抗跌 【2011/11/28 經濟日報】生技族群不受景氣衝擊，華廣（4737）、泰博、五鼎等血糖測試族群，更受惠全球糖尿病人口與日增影響，法人表示，明年即使景氣持續下滑，也將不會受到影響；血糖測試族群等醫材類產業，可望成為「儲蓄概念股」。 五鼎生技董事長沈燕士昨（27）日表示，目前除了先進國家患糖尿病人口比重在15%左右，就連一般新興國家也都成為糖尿病大國。他說，五鼎正在美國及大陸外，積極開發新興市場；印度、南美、中東等地區，都已經躍升為重要銷售對象。 沈燕士說，目前五鼎在印度有代理商，巴西也開始接洽，中東的營收占比也在5%左右，各地的市場潛力都很大，糖尿病患者對血糖量測的需求，受全球不景氣影響最小。

News from China

Dear Editor:

I hope this email finds you well.

My name is Oliver Haiqing Hua, an Economist, Business Consultant, Report Writer from China.

China is definitely a market not to be ignored. Therefore, I would dare to suggest you to use me to be your reporter for the news and critics from China since there are so many actions happens daily in China which would be interesting for your audience to know, and I have the experience and skill to report on the most interesting stories for your publication.

Please visit my blogs to know more about me:

My blog in Chinese:    http://blog.sina.com.cn/chinesecanadian
My blog in English:     http://blog.sina.com.cn/chinamarketreview
My blog in English:     http://newsfromchina.blog.com/about/
My blog in English:     http://www.eegoes.com/user/haiqing.hua

Presently, I have been working for the following organizations as their reporters, representatives in China on freelance base:
China Representative: http://www.wtcindustries.com
China Representative: http://www.jeccomposites.com
China Representative: http://www.abnnewswire.com
China Representative: http://www.caraway.ie
China Representative: http://www.intlmonetary.com

26 Years Expertise: Economics, Government, Technology, Industries, Marketing, Finance, R&D, Networking, Sourcing, Investigation, Management, Distribution, Sales, Inspection, Technical Support, Reports Writing, Publishing, Teaching ... ...

I hope I can be included in your network and make contributions with my expertise for your business growth and my personal income to make ends meet.

I have educated and worked in China and Canada. I have systematic knowledge of logistics, accounting, finance, investment, and marketing. I have experience in engineering projects for a broad range of industries. I have strong analytical and quantitative skills.

I have excellent organization, negotiation, verbal and written presentation skills, and extensive IT skills. Recently, I have worked as an independent business consultant for Kam controls, Willburt company, United Rotary Brushes, Top Technology, have contributed the business start up in China , marketing effort in USA , Asia, and Europe.

My successful customers include Oil industry, Military, mobile communication, electronics, civil, construction, Chemical.I am specializes in market research and consulting service for enterprise marketing. I have provided special market research services like competitive information, competitive strategy, product testing, brand construction, satisfaction research, mystery customer, store monitoring, and advertisement effect evaluation in more than 20 industries, including IT, communication, home appliance, automobile, real estate, pharmaceutical, energy, chemical, finance, and manufacturing, etc.

I have provided management consulting services for 50 enterprises. The industries served include real estate, power, chemical, steel & iron, furniture, food, mechanical, finance, engineering, garment, tourism, agriculture, electronics, and logistics, etc.

The areas served include management consulting on enterprise strategy and its implementation and consulting on marketing management, business process, human resources management, SMB development, and investment, etc. These experiences provide me with extraordinary capacity on management consulting. With the accumulation of consulting results, we are capable of providing enterprises with comprehensive management solutions on a large scale.

To create  the broadest international vision together with the companies with a farthest plan for globalization and international development. To promote the "management transformation" of enterprises, to upgrade their management capacity, and to work together with our customers for creating first class enterprises. To provide you with sound foundation for decision-making and management consulting for planning your business in a long term through market research.

I believe I would be a good match with your company and that I would be able to live up to your expectations. I am excited by the prospect of an opportunity to contribute my years of knowledge, skills, and experience to the success of your business and I sincerely hope you look upon my application favorably.

Kind Regards,
Oliver

Oliver Haiqing Hua
email: haiqing1@yahoo.com
Skype: oliverhua1
cell in China: +86-137-01879982

I strongly believe what they said in their website: "If you leave this subject for another day, when you have time for it, then most likely you will never get around to it until it is too late. Too late, is when you realize that you should of done this a long time ago.  Too late, is when you realize that your competition has overtaken you. Too late, is when your business stops growing and you start to thinking of letting people go. There is no need to let things go that way. "

中化提供原料藥口服mTOR抑制劑 (Ridaforolimus) 給MERCK 估計貢獻1億台幣

客戶新藥貢獻，中化生明年營收估重回成長  精實新聞 2011-11-24看好客戶新藥需求，原料藥廠中化生(1762)明年營收可望恢復成長，法人估計，年增率有機會挑戰15-20%，重回另一個成長循環的高峰。而最受關注與國際大廠Merck攜手的骨癌新藥，目前已進入歐盟及美國FDA的技術審查，以4-6個月期限估算，最快年底有望取得藥證。中化生今年前10月營收9.79億元，年減3%，一方面受到台幣兌美元升值影響，另方面則是客戶出貨排程的問題。不過，在免抑制劑Tacrolimus開始擴大交貨下，該公司10月營收衝上1.16億元，創下2010年8月以來新高，法人也估計，本季營收可望第三季高峰，全年營收上看11.7億元。展望明年，中化生配合客戶開發新藥或新適應症的布局，可望逐步開花結果，特別是在免抑制劑、真菌、慢性病等領域，已逐步取得國際知名度，吸引國際大廠主動來台尋求協助。其中免抑制劑部分，與Merck合作的RAPA系列，首個適應症骨癌，藥證已進入歐盟及美國FDA的技術審查階段，以4-6個月審查期估算，獲批准時間應落在今年底至明年2月間。法人保守估計，該藥品明年出貨至少將有25-30公斤，以1公斤超過10萬美元估算，營收貢獻將至少1億台幣起跳。其他免抑制劑部分，除今年9、10月開始交貨的Tacrolimus，明年挹注擴大外，內部也看好三項新藥品的需求，包括免抑制劑Everolimus及抗真菌系列，原廠專利都將在2015年逐步到期，學名藥客戶可望提前切入臨床，需求增溫。另外一項老藥新適應症部分，主要用於抗膽固醇，但該公司表示，受限於保密協定，還不能對外透露。法人預期，在客戶可望取得新藥證及免抑制劑、真菌系列產品全球市佔率加溫下，中化生明年營收可望恢復成長，年增幅度挑戰15-20%，突破13億元，創下成立新高。且因高門檻的產品出貨比重增加，只要台幣兌美元不再大幅走升，毛利率可望同步止跌走揚。

佳醫七星級安養中心 每月6~10萬元!!

佳醫七星級護理之家開幕搶攻高端客層市場  2011/11/24 【台北訊】看準國內長期照護市場商機，首度跨足長照市場的佳醫集團（4104），位於汐止的「七星級」安養中心-「佳醫護理之家」，日前開幕。由於訴求飯店式管家經營模式，未演先轟動，即使上週才取得營運執照，已有不少詢問電話。佳醫集團總裁傅輝東指出，佳醫集團切入長照市場，就以「給自己住」的心情，切身關懷、設計、規劃與經營「佳醫護理之家」，提供老人家身心靈全方位的照顧。他表示，佳醫護理之家裝潢採精品飯店高檔風格，營造輕鬆舒適的休閒氛圍，並引進飯店式住房管理，所有照護「管家」均需受過專業禮儀與護理訓練，專人專責、高規格照護住民的生活需求。此外，該護理之家引進智慧型照護系統與遠距探視系統，讓銀髮照護更體貼人性。並與資策會合作推動「體感復健」軟體應用，將復健化成娛樂，不再枯燥乏味。佳醫集團ABH執行長陳啟修指出，佳醫護理之家專攻高階長照市場，床位約180床，主要鎖定需要長期照護，又要求頂級生活品質的客層，甚至有一對一的專人照護，目前每月每人收費約6到10萬元不等。目標是三年開設10家，並計畫明年登錄興櫃。